FDA delays decision on Intercept's liver drug; Alimera reportedly up for sale;

@FierceBiotech: 'Lies, deceit and greed': Martin Shkreli blasted by the feds for Ponzi scheme. More | Follow @FierceBiotech

@JohnCFierce: AstraZeneca hit with another setback as durvalumab disappoints on lung cancer. Report | Follow @JohnCFierce

@DamianFierce: Hear me out: José Mourinho for  CEO. | Follow @DamianFierce

> The FDA extended its review of Intercept Pharmaceuticals' ($ICPT) treatment for primary biliary cirrhosis, adding three months to a process that was previously to conclude on Feb. 29. News

> Alimera Sciences ($ALIM) is looking into selling itself, Reuters reports. Story

> Ariad Pharmaceuticals ($ARIA) appointed Merck KGaA executive Paris Panayiotopoulos to serve as its next CEO, replacing founder Harvey Berger effective Jan. 1. More

> Merck ($MRK) is expecting to win European approval for its hepatitis C combination treatment by mid-2016. The company is in line for FDA approval by Jan. 28. Item

Medical Device News

@FierceMedDev: VA signs onto ReWalk Robotics' exoskeleton device for paralyzed veterans. Report | Follow @FierceMedDev

@EmilyWFierce: Toxin from sea algae impacts memory, behavior in California sea lions: Study. FierceAnimalHealth story | Follow @EmilyWFierce

> FDA approves Zoll's wearable defibrillator for use in children. More

> Gelesis drops IPO, raises $31.5M for pivotal U.S. trial of hydrogel weight-loss capsule. Story

> Philips' Volcano to keep Sacramento site despite 60 manufacturing layoffs. Article

Pharma News

@FiercePharma: Drug costs soar as China tops world ranking in cancer. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Will prosecutors recommend 5000% increase in jail time in specific cases of pharma securities fraud? More | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Shire prepared to walk on Baxalta talks if deal doesn't come soon: WSJ. Story | Follow @CarlyHFierce

> U.S. shells out more for top-selling drugs, even when rebates are factored in: Bloomberg. More

> EMA warns of PML, cancer risks from Novartis' Gilenya. Story

> Amgen wins quick EU approval for Imlygic, its first-in-class immuno-oncology drug. Article

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.